Showing 1 - 10 of 1,850
Persistent link: https://www.econbiz.de/10011751722
Background: Targeting efforts aimed at increasing access to care for the poorest by reducing to a minimum or completely eliminating payments at point of use are increasingly being adopted across low and middle income countries, within the framework of Universal Health Coverage policies. No...
Persistent link: https://www.econbiz.de/10011896552
Background: Valuation is a critical part of the costing process in health economic evaluations. However, an overview of specific issues relevant to the European context on harmonizing methodological requirements for the valuation of costs to be used in health economic evaluation is lacking. We...
Persistent link: https://www.econbiz.de/10013329785
Persistent link: https://www.econbiz.de/10013463124
Persistent link: https://www.econbiz.de/10014328039
Persistent link: https://www.econbiz.de/10011317762
Background: Icatibant is the only subcutaneous treatment for acute Type I and Type II hereditary angioedema with C1-esterase inhibitor deficiency (HAE-C1-INH) licensed for self-administration in Europe. Aim: To compare the economic impact of two icatibant administration strategies: health...
Persistent link: https://www.econbiz.de/10009755347
Background: Rotavirus gastroenteritis (RVGE) is a frequent disease in young children. The recommended German paediatric immunisation schedule does not currently include rotavirus vaccination. A lack of economic data on the impact of routine vaccination is stated as one of the reasons. As a...
Persistent link: https://www.econbiz.de/10010242226
: For modelling, the discrete event technique was used. The model takes outpatient care as well as inpatient care into …
Persistent link: https://www.econbiz.de/10010242232
Persistent link: https://www.econbiz.de/10011486230